4D Molecular Therapeutics (FDMT) FCF Margin (2020 - 2025)
Historic FCF Margin for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Q3 2025 value amounting to 51563.33%.
- 4D Molecular Therapeutics' FCF Margin rose 9874033300.0% to 51563.33% in Q3 2025 from the same period last year, while for Sep 2025 it was 154209.17%, marking a year-over-year increase of 5326026000.0%. This contributed to the annual value of 373975.68% for FY2024, which is 3735965700.0% down from last year.
- According to the latest figures from Q3 2025, 4D Molecular Therapeutics' FCF Margin is 51563.33%, which was up 9874033300.0% from 289620.0% recorded in Q2 2025.
- Over the past 5 years, 4D Molecular Therapeutics' FCF Margin peaked at 132626.32% during Q4 2023, and registered a low of 4681200.0% during Q4 2024.
- Its 5-year average for FCF Margin is 371890.59%, with a median of 9704.03% in 2023.
- Per our database at Business Quant, 4D Molecular Therapeutics' FCF Margin tumbled by 2000000000bps in 2024 and then surged by 2000000000bps in 2025.
- Quarter analysis of 5 years shows 4D Molecular Therapeutics' FCF Margin stood at 29273.91% in 2021, then skyrocketed by 94bps to 1869.05% in 2022, then surged by 7196bps to 132626.32% in 2023, then crashed by -3630bps to 4681200.0% in 2024, then skyrocketed by 99bps to 51563.33% in 2025.
- Its FCF Margin was 51563.33% in Q3 2025, compared to 289620.0% in Q2 2025 and 345635.71% in Q1 2025.